Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: A systematic review and cost analysis

Health Technology Assessment

Volumn 17, Issue 40, 2013, Pages 95-135

  Deshpande, S N ^a   Van Asselt, A D I ^b   Tomini, F ^b   Armstrong, N ^a   Allen, A ^a   Noake, C ^a   Khan, K ^c   Severens, J L ^d   Kleijnen, J ^e   Westwood, M E ^a  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FETAL FIBRONECTIN TESTING; FETUS OUTCOME; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; LENGTH OF STAY; META ANALYSIS; PREDICTION; PREMATURE LABOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84885128319     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17400     Document Type: Article

References (121)

1. Berghella V, Hayes E, Visintine J, Baxter JK. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst Rev 2008;4:CD006843. http://dx.doi.org/10.1002/14651858. CD006843.
2. Morrison JJ, Rennie JM. Clinical, scientific and ethical aspects of fetal and neonatal care at extremely preterm periods of gestation. BJOG 1997;104:1341-50. http://dx.doi.org/10.1111/j. 1471-0528.1997.tb11002.x
3. Byrne B, Morrison JJ. Preterm birth. Clin Evid 2004;11:1903-22. http://dx.doi.org/10.1016/j. ajog.2010.10.499.
4. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2003. Natl Vital Stat Rep 2005;54:1-116.
5. McPheeters ML, Miller WC, Hartmann KE, Savitz DA, Kaufman JS, Garrett JM, et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 2005;192:1325-9. http://dx.doi.org/10.1016/j.ajog.2004.12.055.
6. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301. http://dx.doi.org/10.1136/bmj.325.7359.301.
7. Office for National Statistics (ONS). Live births in 2004, selected background data (final), England and Wales. Newport, Wales: ONS; 2004. URL: www.statistics.gov.uk/statbase/Product.asp?vlnk=14010 (cited 13 June 2011).
8. Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA 2000;248:843-9. http://dx.doi.org/10.1001/jama.284.7.843.
9. Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2002 period linked birth/infant death data set. Natl Vital Stat Rep 2004;53:1-30.
10. Honest H, Forbes CA, Duree KH, Norman G, Duffy SB, Tsourapas A, et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2009;13(43).
11. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2006;3: CD000065. http://dx.doi.org/10.1002/14651858.CD000065.
12. Ascarelli MH, Morrison JC. Use of fetal fibronectin in clinical practice. Obstet Gynecol Surv 1997; 52(Suppl. 4):S1-12. http://dx.doi.org/10.1097/00006254-199704000-00024.
13. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325:669-74. http://dx.doi.org/10.1056/NEJM199109053251001.
14. Local Trust Guidelines. Treatment of women presenting in preterm labour. Essex: Basildon and Thurrock University Hospital (BTUH); 2008.
15. Morgan MA, Goldenberg RL, Schulkin J. Obstetrician-gynecologists' knowledge of preterm birth frequency and risk factors. J Matern Fetal Neonatal Med 2007;20:895-901. http://dx.doi.org/ 10.1080/14767050701750498.
16. Andersen HF. Use of fetal fibronectin in women at risk for preterm delivery. Clin Obstet Gynecol 2000;43:746-58.
17. Institute of Health Economics (IHE). Using fetal fibronectin to diagnose pre-term labour. Edmonton, AB: IHE; 2008. p. 79.
18. Ramsey PS, Andrews WW. Biochemical predictors of preterm labor: fetal fibronectin and salivary estriol. Clin Perinatol 2003;30:701-33. http://dx.doi.org/10.1016/S0095-5108(03)00109-X
19. Tucker J, McGuire W. Epidemiology of preterm birth. BMJ 2004;329:675-8. http://dx.doi.org/ 10.1136/bmj.329.7467.675.
20. Haram K, Mortensen JH, Wollen AL. Preterm delivery: an overview. Acta Obstet Gynecol Scand 2003;82:687-704. http://dx.doi.org/10.1034/j.1600-0412.2003.00218.x
21. Logghe H, Walker JJ. Towards improved neonatal outcome: future strategies. Semin Fetal Neonatal Med 2004;9:491-8. http://dx.doi.org/10.1016/j.siny.2004.08.002.
22. Conde-Agudelo A, Romero R. Cervicovaginal fetal fibronectin for the prediction of spontaneous preterm birth in multiple pregnancies: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2010;23:1365-76. http://dx.doi.org/10.3109/14767058.2010.499484.
23. Koenn ME. Fetal fibronectin. Clin Lab Sci 2002;15:96-8.
24. Lee SK, McMillan DD, Ohlsson A, Boulton J, Lee DS, Ting S, et al. The benefit of preterm birth at tertiary care centers is related to gestational age. Am J Obstet Gynecol 2003;188:617-22. http://dx.doi.org/10.1067/mob.2003.139.
25. Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003;101:402-12. http://dx.doi.org/10.1016/S0029-7844(02)02505-X
26. Hole JW, Tressler TB. Management of preterm labor. J Am Osteopath Assoc 2001;101(Suppl. 2): S14-8.
27. Terzidou V, Bennett PR. Preterm labour. Curr Opin Obstet Gynecol 2002;14:105-13. http://dx.doi. org/10.1097/00001703-200204000-00002.
28. Sanchez-Ramos L, Delke I, Zamora J, Kaunitz AM. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis. Obstet Gynecol 2009;114:631-40. http://dx.doi.org/10.1097/AOG.0b013e3181b47217.
29. Medical Services Advisory Committee (MSAC). Fetal fibronectin test for preterm labour. Canberra: MSAC; 2006.
30. Vis JY, Wilms FF, Oudijk MA, Bossuyt PMM, van der Post JAM, Grobman WA, et al. Why were the results of randomized trials on the clinical utility of fetal fibronectin negative? A systematic review of their study designs. Am J Perinatol 2011;28:145-50. http://dx.doi.org/10.1055/s-0030-1263297.
31. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2009. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (cited 23 March 2011).
32. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. J Clin Epidemiol 2011;64:602-7. http://dx.doi.org/10.1016/j.jclinepi.2010.07.006.
33. National Institute for Health and Care Excellence (NICE). Diagnostics Assessment Programme: interim methods statement (version 2). London: NICE; 2010. URL: www.nice.org.uk/media/164/3C/ DAPInterimMethodsStatementProgramme.pdf (cited 12 January 2011).
34. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Inf Pract 2010;5:1-6.
35. Honest H, Forbes CA, Duree KH, Norman G, Duffy SB, Tsourapas A, et al. [Appendices] Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2009;13(43).
36. Zagorac D, Doll K, Schon JC, Jansen M. Ab initio structure prediction for lead sulfide at standard and elevated pressures. Physical Review B 2011;84(4). http://dx.doi.org/10.1103/ PhysRevB.84.045206.
37. Tang ZH, Tadesse S, Norwitz E, Mor G, Abrahams VM, Guller S. Isolation of hofbauer cells from human term placentas with high yield and purity. Am J Reprod Immunol 2011;66:336-48. http://dx.doi.org/10.1111/j.1600-0897.2011.01006.x
38. Taylor BK. Sonographic assessment of cervical length and the risk of preterm birth. J Obstet Gynecol Neonatal Nurs 2011;40:617-31. http://dx.doi.org/10.1111/j.1552-6909.2011.01284.x
39. Cochrane Diagnostic Test Accuracy Working Group. Handbook for DTA reviews. Cochrane Collaboration; 2011. URL: http://srdta.cochrane.org/handbook-dta-reviews (cited 12 January 2011).
40. Solarino G, Piazzolla A, Mori CM, Moretti L, Patella S, Notarnicola A. Alumina-on-alumina total hip replacement for femoral neck fracture in healthy patients. BMC Musculoskelet Disord 2011;12(32).
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. http://dx.doi.org/10.1016/0197-2456(86)90046-2.
42. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org/ (cited 23 March 2011).
43. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022.
44. Harbord RM, Deek JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-51. http://dx.doi.org/10.1093/biostatistics/ kxl004.
45. Moses LE, Shapiro D, Littenberg B. Combining independant studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316. http://dx.doi.org/10.1002/sim.4780121403.
46. Lijmer JG, Bossuyt PMM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002;21:1525-37. http://dx.doi.org/10.1002/sim.1185.
47. Dutta D, Norman JE. Pilot study into the efficacy of foetal fibronectin testing in minimising hospital admissions in women presenting with symptoms of preterm labour: a randomised controlled trial of obstetric and neonatal outcomes. Arch Gynecol Obstet 2011;284:559-65. http://dx.doi.org/ 10.1007/s00404-010-1712-x
48. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center. Am J Obstet Gynecol 2004;190:358-62. http://dx.doi.org/10.1016/j.ajog.2003.08.041.
49. Plaut MM, Smith W, Kennedy K, Nageotte M, DeCastro E, Steinke R, et al. Fetal fibronectin: the impact of a rapid test on the treatment of women with preterm labor symptoms. Am J Obstet Gynecol 2003;188:1588-95. http://dx.doi.org/10.1067/mob.2003.390.
50. Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2004;191:235-40. http://dx.doi.org/10.1016/j.ajog.2003.11.034.
51. Osório M, Neiva R, Montes L, Silva J, Pinelo S, Pinho M, et al. The impact of fetal fibronectin assay on preterm labor management: a randomized controlled trial. Paper presented at 22nd European Congress of Perinatal Medicine; 26-29 May 2010; Granada, Spain. J Matern Fetal Neonatal Med 2010;23:304-5.
52. Hansen W, Lowe MP, Zimmerman B. Effect of the fetal fibronectin assay on preterm labor management. Am J Obstet Gynecol 2001;185(Suppl. 6):S136. http://dx.doi.org/10.1016/S0002- 9378(01)80232-5.
53. Grobman W, Welshman E, Calhoun E. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs. Paper presented at 23rd Annual Meeting of the Society for Maternal-Fetal Medicine; 3-8 Feb 2003; San Francisco, USA. Am J Obstet Gynecol 2003;187(Suppl. 6, Part 2):S80. http://dx.doi.org/10.1016/j.ajog.2003.11.034.
54. Diaz J, Chedraui P, Hidalgo L, Medina M. The clinical utility of fetal fibronectin in the prediction of pre-term birth in a low socio-economic setting hospital in Ecuador. J Matern Fetal Neonatal Med 2009;22:89-93. http://dx.doi.org/10.1080/14767050802464551.
55. Asakura H, Fukami T, Kurashina R, Tateyama N, Doi D, Takeshita T. Significance of cervical gland area in predicting preterm birth for patients with threatened preterm delivery: comparison with cervical length and fetal fibronectin. Gynecol Obstet Invest 2009;68:1-8. http://dx.doi.org/10.1159/ 000209394.
56. Tsoi E, Akmal S, Geerts L, Jeffery B, Nicolaides KH. Sonographic measurement of cervical length and fetal fibronectin testing in threatened preterm labor. Ultrasound Obstet Gynecol 2006;27:368-72. http://dx.doi.org/10.1002/uog.2723.
57. Skoll A, St Louis P, Amiri N, Delisle M-F, Lalji S. The evaluation of the fetal fibronectin test for prediction of preterm delivery in symptomatic patients. J Obstet Gynaecol Can 2006;28:206-13.
58. Desjardins PR, Dansereau J, Hoag GN. Comparing the clinical effectiveness of Fetal Fibronectin and IGFBP-1 measurements in cervico-vaginal secretions, in predicting preterm deliveries. Clin Chem 2008;54:A39-40.
59. Eroglu D, Yanik F, Oktem M, Zeyneloglu HB, Kuscu E. Prediction of preterm delivery among women with threatened preterm labor. Gynecol Obstet Invest 2007;64:109-16. http://dx.doi.org/10.1159/ 000100120.
60. Groom KM, Liu E, Allenby K. The impact of fetal fibronectin testing for women with symptoms of preterm labour in routine clinical practice within a New Zealand population. Aust N Z J Obstet Gynaecol 2006;46:440-5. http://dx.doi.org/10.1111/j.1479-828X.2006.00631.x
61. Henrich W. Cervicometry and fibronectin role. Paper presented at 22nd European Congress of Perinatal Medicine; 26-29 May 2010; Granada, Spain. J Matern Fetal Neonatal Med 2010; 23(Suppl. 1):39.
62. MacDonald WA, Bender M, Saxton A. Use of fetal fibronectin in the management of preterm labour in Nunavut. Alaska Med 2007;49(Suppl. 2):215-17.
63. Swamy GK, Simhan HN, Gammill HS, Heine RP. Clinical utility of fetal fibronectin for predicting preterm birth. J Reprod Med 2005;50:851-6.
64. Audibert F, Fortin S, Delvin E, Djemli A, Brunet S, Dube J, et al. Contingent use of fetal fibronectin testing and cervical length measurement in women with preterm labour. J Obstet Gynaecol Can 2010;32:307-12.
65. Driul L, Cacciaguerra G, Calcagno A, Vascotto L, Pontello D, Marchesoni D. [Pretern delivery predition: use of fetal fribonectin in comparison and association with ultrasound measurement of cervical length and clinically evaluated cervical dilatation.] Ital J Gynecol Obstet 2009;21:81-5.
66. Singer E, Pilpel S, Bsat F, Plevyak M, Healy A, Markenson G. Accuracy of fetal fibronectin to predict preterm birth in twin gestations with symptoms of labor. Obstet Gynecol 2007;109: 1083-7. http://dx.doi.org/10.1097/01.AOG.0000261896.20175.3a
67. Farfan JAL, Tovar HBS, del de Anda MRG, Guevara CG. Fetal fibronectin and cervical length as predictors of early preterm delivery. Ginecol Obstet Mex 2011;79:337-43.
68. Sümer C, Yalvac S, Kandemir O, Karcaaltincaba D, Haberal A. [The predictive value of sonographic cervical length measurement and fetal fibronection testing to determine true preterm labour.] Turk Jinekoloji ve Obstetrik Dernegi Dergisi 2010;7:189-95.
69. Mozurkewich EL, Naglie G, Krahn MD, Hayashi RH. Predicting preterm birth: a cost-effectiveness analysis. Am J Obstet Gynecol 2000;182:1589-97. http://dx.doi.org/10.1067/mob.2000.106855.
70. Revah A, Hannah ME, Sue AQAK. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perinatol 1998;15:613-21. http://dx.doi.org/10.1055/s-2007-994079.
71. Tsourapas A, Roberts TE, Barton PM, Honest H, Forbes C, Hyde CJ, et al. An economic evaluation of alternative test-intervention strategies to prevent spontaneous pre-term birth in singleton pregnancies. Acta Obstet Gynecol Scand 2009;88:1319-30. http://dx.doi.org/10.3109/ 00016340903410873.
72. Department of Health (DoH). NHS reference costs 2009-10. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (cited 15 March 2010).
73. Beta distribution. Wikipedia: The Free Encyclopedia, Wikimedia Foundation; 2012. URL: http://en.wikipedia.org/wiki/Beta_distribution (cited 7 March 2012).
74. Curtis L. Unit costs of health and social care 2011. Canterbury: Personal Social Services Research Unit; 2011. URL: www.pssru.ac.uk/uc/uc2011contents.htm (cited 1 March 2012).
75. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 62, September 2011. London: BMA and RPS; 2011. URL: http://bnf.org/ (cited 14 February 2012).
76. Curtis L. Unit costs of health and social care 2010. Canterbury: Personal Social Services Research Unit; 2010.
77. Duley L, Bennett P. Tocolysis for women in preterm labour. Green-top Guideline No. 1b [Internet]: Royal College of Obstetricians and Gynaecologists; February 2011. URL: www.rcog.org.uk/files/ rcog-corp/GTG1b26072011.pdf (cited 14 February 2012).
78. Roberts D. Antenatal corticosteroids to reduce neonatal morbidity and mortality. Green-top Guideline No. 7. Royal College of Obstetricians and Gynaecologists; 2010. URL: www.rcog.org.uk/files/rcog-corp/GTG%207.pdf (cited 14 February 2012).
79. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882-93. http://dx.doi.org/10.1016/j.jclinepi.2005.01.016.
80. Lopez Farfan JA, Sanchez Tovar HB, Gutierrez de Anda MdR, Gamez Guevara C. [Fetal fibronectin and cervical length as early predictors of preterm labor.] Ginecol Obstet Mex 2011;79:337-43.
81. Bartnicki J, Casal D, Kreaden US, Saling E, Vetter K. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am J Obstet Gynecol 1996;174: 971-4. http://dx.doi.org/10.1016/S0002-9378(96)70335-6.
82. Benattar C, Taieb J, Fernandez H, Lindendaum A, Frydman R, Ville Y. Rapid fetal fibronectin swab-test in preterm labor patients treated by betamimetics. Eur J Obstet Gynecol Reprod Biol 1997;72:131-5. http://dx.doi.org/10.1016/S0301-2115(96)02673-5
83. Closset E, Dufour P, Coeugnet C, Subtil D, Valat AS, Puech F. [Value of fetal fibronectin research for predicting premature delivery.] Gynecol Obstet Fertil 2001;29:808-13.
84. Foxman EF, Jarolim P. Use of the fetal fibronectin test in decisions to admit to hospital for preterm labor. Clin Chem 2004;50:663-5. http://dx.doi.org/10.1373/clinchem.2003.028720.
85. Giles W, Bisits A, Knox M, Madsen G, Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000;182:439-42. http://dx.doi.org/10.1016/S0002-9378(00)70236-5.
86. Gomez R, Romero R, Medina L, Nien JK, Chaiworapongsa T, Carstens M, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005;192:350-9. http://dx.doi.org/10.1016/j.ajog.2004.09.034.
87. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, Lowensohn R, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995;173:141-5. http://dx.doi.org/10.1016/0002-9378(95)90182-5.
88. LaShay N, Gilson G, Joffe G, Qualls C, Curet L. Will cervicovaginal interleukin-6 combined with fetal fibronectin testing improve the prediction of preterm delivery? J Matern Fetal Med 2000;9:336-41. http://dx.doi.org/10.3109/14767050009018422.
89. Lopez RL, Francis JA, Garite TJ, Dubyak JM. Fetal fibronectin detection as a predictor of preterm birth in actual clinical practice. Am J Obstet Gynecol 2000;182:1103-6. http://dx.doi.org/10.1067/ mob.2000.105411.
90. Luzzi V, Hankins K, Gronowski AM. Accuracy of the rapid fetal fibronectin TLi system in predicting preterm delivery. Clin Chem 2003;49:501-2. http://dx.doi.org/10.1373/49.3.501.
91. Malak TM, Sizmur F, Bell SC, Taylor DJ. Fetal fibronectin in cervicovaginal secretions as a predictor of preterm birth. Br J Obstet Gynaecol 1996;103:648-53. http://dx.doi.org/10.1111/j.1471-0528.1996.tb09832.x
92. McKenna DS, Chung K, Iams JD. Effect of digital cervical examination on the expression of fetal fibronectin. J Reprod Med 1999;44:796-800.
93. Peaceman AM, Andrews WW, Thorp JM, Cliver SP, Lukes A, Iams JD, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997;177:13-18. http://dx.doi.org/10.1016/S0002-9378(97)70431-9.
94. Sakai M, Sasaki Y, Yamagishi N, Tanebe K, Yoneda S, Saito S. The preterm labor index and fetal fibronectin for prediction of preterm delivery with intact membranes. Obstet Gynecol 2003;101:123-8. http://dx.doi.org/10.1016/S0029-7844(02)02463-8.
95. Senden IP, Owen P. Comparison of cervical assessment, fetal fibronectin and fetal breathing in the diagnosis of preterm labour. Clin Exp Obstet Gynecol 1996;23:5-9.
96. Tekesin I, Marek S, Hellmeyer L, Reitz D, Schmidt S. Assessment of rapid fetal fibronectin in predicting preterm delivery. Obstet Gynecol 2005;105:280-4. http://dx.doi.org/10.1097/01. AOG.0000150557.00298.47.
97. Burrus DR, Ernest JM, Veille JC. Fetal fibronectin, interleukin-6, and C-reactive protein are useful in establishing prognostic subcategories of idiopathic preterm labor. Am J Obstet Gynecol 1995;173:1258-62. http://dx.doi.org/10.1016/0002-9378(95)91366-1.
98. Chuileannain FN, Bell R, Brennecke S. Cervicovaginal fetal fibronectin testing in threatened preterm labour - translating research findings into clinical practice. Aust N Z J Obstet Gynaecol 1998;38:399-402. http://dx.doi.org/10.1111/j.1479-828X.1998.tb03096.x
99. Cox S, Little B, Dax J, Leveno K. Fetal fibronectin and preterm delivery. Am J Obstet Gynecol 1996;174:306(S).
100. Goffeng AR, Holst E, Milsom I, Lindstedt G, Lundberg PA, Andersch B. Fetal fibronectin and microorganisms in vaginal fluid of women with complicated pregnancies. Acta Obstet Gynecol Scand 1997;76:521-7. http://dx.doi.org/10.3109/00016349709024576.
101. Musaad SMA, Melson CL, Boswell DR. Assessment of the impact of introducing fetal fibronectin assay in the management of preterm labour at Middlemore Hospital, New Zealand. Pathology 2005;37:226-30. http://dx.doi.org/10.1080/00313020500099056.
102. Parker J, Bell R, Brennecke S. Fetal fibronectin in the cervicovaginal fluid of women with threatened preterm labour as a predictor of delivery before 34 weeks' gestation. Aust N Z J Obstet Gynaecol 1995;35:257-61. http://dx.doi.org/10.1111/j.1479-828X.1995.tb01976.x
103. Calda P, Cibula D, Doudova D, Binder T, Peterka T, Zizka Z, et al. [Fetal fibronectin in cervico-vaginal secretions-an indicator of incipient premature labor using a membrane immunoassay.] Ceska Gynekol 1995;60:293-5.
104. Pieta-Dolinska A, Jaczewski B, Wozniak P, Oszukowski P. [Evaluation of fetal fibronectin concentration in identifying patients at risk for preterm delivery.] Ginekol Pol 2005;76:431-5.
105. Grandi C, Perego M, Briozzo G, Cassini A. [Fetal fibronectin (fFN) in cervical secretions as a predictor of premature delivery.] Rev Hosp Mat Inf Ramon Sarda 1996;15:127-36.
106. Hincz P, Wilczynski J, Kozarzewski M, Szaflik K. Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of preterm delivery in symptomatic patients. Acta Obstet Gynecol Scand 2002;81:58-63. http://dx.doi.org/10.1034/j.1600-0412.2002.810111.x
107. Inglis SR, Jeremias J, Kuno K, Lescale K, Peeper Q, Chervenak FA, et al. Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am J Obstet Gynecol 1994;171:5-10. http://dx.doi.org/10.1016/S0002-9378 (94)70069-9.
108. Irion O, Matute J, Bischof P. [Prediction of prematurity by oncofetal fibronectin. Prospective cohort study.] J Gynecol Obstet Biol Reprod 1995;24:624-9.
109. Langer B, Boudier E, Schlaeder G. Cervico-vaginal fetal fibronectin: predictive value during false labor. Acta Obstet Gynecol Scand 1997;76:218-21. http://dx.doi.org/10.1111/j.1600-0412.1997. tb07848.x
110. Mansouri A, Tadjerouni A, El Rabiey G, Baube S, Garnier G, Tribalat S. [Is fetal fibronectin a valid test predictive of premature labor?] Fertilite Contraception Sexualite 1997;25:380-4.
111. Morrison JC, Allbert JR, McLaughlin BN, Whitworth NS, Roberts WE, Martin RW. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol 1993;168:538-42. http://dx.doi.org/10.1016/0002-9378(93)90488-5.
112. Rizzo G, Capponi A, Vlachopoulou A, Angelini E, Grassi C, Romanini C. The diagnostic value of interleukin-8 and fetal fibronectin concentrations in cervical secretions in patients with preterm labor and intact membranes. J Perinat Med 1997;25:461-8. http://dx.doi.org/10.1515/jpme.1997.25.6.461.
113. Rozenberg P, Goffinet F, Malagrida L, Giudicelli Y, Perdu M, Houssin I, et al. Evaluating the risk of preterm delivery: a comparison of fetal fibronectin and transvaginal ultrasonographic measurement of cervical length. Am J Obstet Gynecol 1997;176(Part 1):196-9. http://dx.doi.org/10.1016/S0002- 9378(97)80035-X DOI: 10.3310/hta17400 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 40. 57 © Queen's Printer and Controller of HMSO 2013. This work was produced by Deshpande et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16. 7NS, UK.
114. Stevens AO, Chauhan SP, Magann EF, Martin RW, Bofill JA, Cushman JL, et al. Fetal fibronectin and bacterial vaginosis are associated with preterm birth in women who are symptomatic for preterm labor. Am J Obstet Gynecol 2004;190:1582-7. discussion 1587-9. http://dx.doi.org/10.1016/j. ajog.2004.03.059.
115. Gomez-Bravo Topete E, Castillo-Lechuga C, Villegas-Su A, Briones-Garduno JC. [Predictive value of fetal fibronectin for preterm labor.] Cir Cir 2004;72:491-4.
116. Vercoustre L, Sotter S, Bouige D, Walch R. [Fibronectin as a predictor of labor, results and discussion about 206 samples.] Gynecol Obstet Fertil 1996;4:23-32.
117. Vetr M, Kudela M, Prasilova J. Fetal fibronectin in patients at increased risk for premature birth. Acta Univ Palacki Olomuc Fac Med 1996;140:55-7.
118. No. 179 - consumer price indexes of medical care prices: 1980-1997. In Statistical abstracts of the United States US Census Bureau. Washington, DC: United States US Census Bureau; 1998.
119. Haddix AC, Teutsch SM, Corso PS, editors. Appendix F: cost-to-charge ratios. In Prevention effectiveness. New York, NY: Oxford University Press; 1996. p. 181.
120. Backhouse M, Mauskopf J, Jones D, Wold D, Schumacher R, Cotton R, et al. Economic outcomes of bolfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome. Pharmacoeconomics 1194;6:358-69.
121. Myers ER, Alvarez JG, Richardson DK, Ludmir J. Cost-effectiveness of fetal lung maturity testing in preterm labor. Obstet Gynecol 1997;90:824-9. http://dx.doi.org/10.1016/S0029-7844(97)00412-2